In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.
Dugel explained how the implant is designed to address unmet needs in sustainability.
“We firmly believe that not only will we improve sustainability and be able to treat a lot more patients who deserve this treatment, but we believe that we will also be able to improve outcomes,” he said.